StockData
Amneal Pharmaceuticals, Inc. logo

Amneal Pharmaceuticals, Inc. (AMRX) stock

AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3063% above fair value
$21.12−0.11 (-0.52%)

Close on Nov 17, 2026Market cap $6.74BP/E 43.1Yield –

Amneal Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Amneal Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was $200.78M, down 42.8% year over year. For fiscal 2025 it was $339.99M, up 15.2% from the year before. The highest annual figure on record is $379.00M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$339.99M+15.2%
FY2024Dec 31, 2024$295.10M-14.6%
FY2023Dec 31, 2023$345.58M+430.8%
FY2022Dec 31, 2022$65.10M-73.1%
FY2021Dec 31, 2021$241.82M-36.2%
FY2020Dec 31, 2020$379.00M+22128.8%
FY2019Dec 31, 2019$1.71M-99.3%
FY2018Dec 31, 2018$250.23M+6.9%
FY2017Dec 31, 2017$234.19M+103.5%
FY2016Dec 31, 2016$115.06M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$21.24M-125.3%
Q1 FY2026Mar 31, 2026-$26.74M-461.0%
Q4 FY2025Dec 31, 2025$130.32M+10.4%
Q3 FY2025Sep 30, 2025$118.45M-16.5%
Q2 FY2025Jun 30, 2025$83.82M+111.4%
Q1 FY2025Mar 31, 2025$7.41M–
Q4 FY2024Dec 31, 2024$118.08M-13.1%
Q3 FY2024Sep 30, 2024$141.77M+74.2%
Q2 FY2024Jun 30, 2024$39.66M–
Q1 FY2024Mar 31, 2024-$4.41M-103.2%
Q4 FY2023Dec 31, 2023$135.82M–
Q3 FY2023Sep 30, 2023$81.39M-13.0%
Q2 FY2023Jun 30, 2023-$11.35M–
Q1 FY2023Mar 31, 2023$139.71M+16.1%
Q4 FY2022Dec 31, 2022-$23.29M-136.8%
Q3 FY2022Sep 30, 2022$93.57M+13.6%
Q2 FY2022Jun 30, 2022-$125.52M–
Q1 FY2022Mar 31, 2022$120.34M-18.8%
Q4 FY2021Dec 31, 2021$63.26M-40.3%
Q3 FY2021Sep 30, 2021$82.36M+83.9%
Q2 FY2021Jun 30, 2021-$51.93M-129.0%
Q1 FY2021Mar 31, 2021$148.13M+202.1%
Q4 FY2020Dec 31, 2020$105.96M–
Q3 FY2020Sep 30, 2020$44.78M-68.0%
Q2 FY2020Jun 30, 2020$179.24M+749.7%
Q1 FY2020Mar 31, 2020$49.03M–
Q4 FY2019Dec 31, 2019-$50.89M-119.6%
Q3 FY2019Sep 30, 2019$139.91M+125.2%
Q2 FY2019Jun 30, 2019$21.09M–
Q1 FY2019Mar 31, 2019-$108.41M-501.1%
Q4 FY2018Dec 31, 2018$259.65M–
Q3 FY2018Sep 30, 2018$62.13M-15.5%
Q2 FY2018Jun 30, 2018-$98.58M–
Q1 FY2018Mar 31, 2018$27.03M–
Q4 FY2017Dec 31, 2017$0–
Q3 FY2017Sep 30, 2017$73.51M–

More Amneal Pharmaceuticals figures

See a number that looks wrong?